Promazine

{{Short description|Chemical compound}}

{{cs1 config|name-list-style=vanc}}

{{Distinguish|Bromazine}}

{{Drugbox

| verifiedrevid = 464215585

| IUPAC_name = N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine

| image = Promazine.svg

| image_class = skin-invert-image

| width = 160

| image2 = Promazine3d.png

| image_class2 = bg-transparent

| tradename =

| Drugs.com = {{drugs.com|CONS|promazine}}

| MedlinePlus = a600010

| pregnancy_category =

| legal_AU =

| legal_BR = C1

| legal_BR_comment = {{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2023-04-04}}

| legal_CA =

| legal_DE =

| legal_NZ =

| legal_UK =

| legal_US =

| legal_EU =

| legal_UN =

| legal_status =

| routes_of_administration =

| class = Typical antipsychotic

| bioavailability =

| protein_bound = 94%

| metabolism =

| elimination_half-life = 20-40 hr

| excretion =

| IUPHAR_ligand = 7281

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 58-40-2

| ATC_prefix = N05

| ATC_suffix = AA03

| ATC_supplemental =

| PubChem = 4926

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00420

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 4757

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = O9M39HTM5W

| KEGG = D08430

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEBI = 8459

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 564

| C=17 | H=20 | N=2 | S=1

| SMILES = CN(C)CCCN1c2ccccc2Sc3c1cccc3

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = ZGUGWUXLJSTTMA-UHFFFAOYSA-N

}}

Promazine (brand name Sparine among others), is used as a short-term add-on treatment for psychomotor agitation.{{cite book | vauthors = Davis C | title = X Pharm: The Comprehensive Pharmacology Reference | veditors = Enna SJ, Bylund DB |chapter=Promazine |date=2007 |publisher=Elsevier |isbn=978-0-08-055232-3 |pages=1–6 | doi = 10.1016/B978-008055232-3.62472-9 }} Its approved uses in people is limited, but is used as a tranquilizer in veterinary medicine. It has weak antipsychotic effects but is generally not used to treat psychoses.

It acts similar to chlorpromazine and causes sedation. It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon. It belongs to the typical antipsychotic and phenothiazine class of drugs.{{cite book | vauthors = Pagliaro LA, Pagliaro AM | chapter = PPDR: Promazine |title=Psychologist's Neuropsychotropic Desk Reference |date=1999 |publisher=Brunner/Mazel |location=Philadelphia |isbn=978-1-138-00968-4 |page=535 |chapter-url=https://books.google.com/books?id=n2e2aAYnZYkC&pg=PA535}}

Promazine was approved for medical use in the United States in the 1950s, although it is no longer commercially available there.{{cite web |title=Promazine (Primazine, Prozine) | work = Davis's Drug Guide |url=https://www.drugguide.com/ddo/view/Davis-Drug-Guide/109132/all/promazine |access-date=6 August 2021 |language=en}}{{cite web | title = Drugs@FDA: FDA-Approved Drugs | work = New Drug Application (NDA): 010942 Sparine | url = https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010942 | archive-url = https://web.archive.org/web/20170430204918/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010942 | url-status = dead | archive-date = April 30, 2017 | publisher = U.S. Food and Drug Administration }}